Clinical Trial Update: PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial [Phase 2]

View source ↗

Summary

Phase II open-label study evaluating PD-1 inhibitors plus chemoradiotherapy in metastatic nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• PD-1 inhibitors

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Nasopharyngeal Carcinoma, PD-1 Inhibitors | Phase 2 | Status: UNKNOWN